Mutations of BTG1 and BRAF, deletions of CDNK2A/B and amplification of PD-L1 were all identified in samples from venetoclax-resistant patients, suggesting there may be multiple mechanisms that confer resistance to venetoclax in CLL. Here, CD274 is linked to B-cell chronic lymphocytic leukemia.